Abbott has announced that data from a new study has shown that two blood-based biomarkers measured using its tests were able to predict a patient’s recovery from traumatic brain injury (TBI).
The company stated that testing for these two biomarkers immediately after an injury can help doctors determine the best treatments and care for patients.
In the study, published in The Lancet Neurology, Abbott’s i-STAT TBI Plasma test and its ARCHITECT core laboratory instrument were used to measure the two biomarkers in a blood sample.
It demonstrated that clinicians could get a more precise picture of the injury, the expected course of recovery and the long-term effects of the TBI by performing the blood test soon after an injury.
The researchers evaluated the glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) levels in the blood plasma within 24 hours of an injury.
After evaluating the biomarker levels on the day of the injury, they assessed patients for six months.
The researchers kept track of biomarker levels as well as how patients fared during their recovery.
University of Michigan emergency medicine associate professor Dr Fred Korley said: “Brain injury biomarkers will one day be the standard of care to evaluate and treat patients.
“Objective biomarker data can be profoundly helpful in determining prognosis for a patient, helping to gauge how severe a brain injury is, and can ultimately inform how best to counsel family members about care for their loved ones with brain injury.”
The researchers compared 1,696 TBI patients’ day-of-injury blood tests with their six-month assessment using the Glasgow Outcome Scale Extended, which rates the outcomes and quantifies the disability levels after TBI.
They discovered that high biomarker values for UCH-L1 and GFAP correlated with death and serious injury.
The day-of-injury blood tests showed a high chance of predicting death at six months, with 87% for GFAP and 89% for UCH-L1, as well as a high likelihood of predicting serious disability, with 86% for GFAP and UCH-L1.
In June, Abbott received US Food and Drug Administration (FDA) approval for its next-generation FreeStyle Libre 3 system for use by diabetic patients.